SOD2
肾脏疾病
医学
急性肾损伤
肾
缺氧诱导因子
缺氧(环境)
血管内皮生长因子
药理学
缺血
血管内皮生长因子A
内科学
内分泌学
氧化应激
超氧化物歧化酶
生物
化学
血管内皮生长因子受体
生物化学
氧气
有机化学
基因
作者
Mengqiu Wu,Wei‐Yi Chen,Mengqiu Miao,Qianqian Jin,Shengnan Zhang,Mi Bai,Jinhui Fan,Yue Zhang,Aihua Zhang,Zhanjun Jia,Songming Huang
出处
期刊:Clinical Science
[Portland Press]
日期:2021-07-01
卷期号:135 (14): 1707-1726
被引量:30
摘要
Abstract Acute kidney injury (AKI) is a known risk factor for the development of chronic kidney disease (CKD), with no satisfactory strategy to prevent the progression of AKI to CKD. Damage to the renal vascular system and subsequent hypoxia are common contributors to both AKI and CKD. Hypoxia-inducible factor (HIF) is reported to protect the kidney from acute ischemic damage and a novel HIF stabilizer, FG4592 (Roxadustat), has become available in the clinic as an anti-anemia drug. However, the role of FG4592 in the AKI-to-CKD transition remains elusive. In the present study, we investigated the role of FG4592 in the AKI-to-CKD transition induced by unilateral kidney ischemia–reperfusion (UIR). The results showed that FG4592, given to mice 3 days after UIR, markedly alleviated kidney fibrosis and enhanced renal vascular regeneration, possibly via activating the HIF-1α/vascular endothelial growth factor A (VEGFA)/VEGF receptor 1 (VEGFR1) signaling pathway and driving the expression of the endogenous antioxidant superoxide dismutase 2 (SOD2). In accordance with the improved renal vascular regeneration and redox balance, the metabolic disorders of the UIR mice kidneys were also attenuated by treatment with FG4592. However, the inflammatory response in the UIR kidneys was not affected significantly by FG4592. Importantly, in the kidneys of CKD patients, we also observed enhanced HIF-1α expression which was positively correlated with the renal levels of VEGFA and SOD2. Together, these findings demonstrated the therapeutic effect of the anti-anemia drug FG4592 in preventing the AKI-to-CKD transition related to ischemia and the redox imbalance.
科研通智能强力驱动
Strongly Powered by AbleSci AI